$8.13
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases
Overview
52-week range
$5.60
$16
25% of range
Avg surprise (last 2)
+77.2%
Avg reaction (last 1)
+2.7%
100% positive
Latest IV / EM
191%
EM ±43.7% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-1.46 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-1.38 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.50 | $-0.76 | +165.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.68 | $-0.61 | -11.5% | — | +2.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.54 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-10.50 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.74 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.82 | $0.50 | -264.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78,000 | — | $452,000 | $298,000 | $1M | — | $387,000 | $33M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-26M | — | $-21M | $-22M | $-22M | — | $-18M | $14M |
| Net income | $-39M | — | $-36M | $16M | $-18M | — | $-24M | $14M |
| EPS (diluted) | $-1.46 | — | $-1.38 | $0.50 | $-0.68 | — | $-1.13 | $0.54 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $119M | $125M | $143M | $160M | $180M | $213M | $219M | $87M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $122M | $129M | $147M | $163M | $185M | $217M | $229M | $125M |
| Total assets | $288M | $296M | $373M | $389M | $409M | $435M | $455M | $348M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $437M | $423M | $409M | $391M | $431M | $442M | $455M | $449M |
| Total equity | $-148M | $-126M | $-36M | $-3M | $-22M | $-7M | $752,000 | $-101M |